Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging Human Monkeypox Virus

키워드

참고문헌 (112)

1. McCollum AM, "Human Monkeypox", Clin. Infect. Dis, 58, pp.260~267 (2013)
2. "2022-23 Mpox outbreak: Global Trends" (2023)[URL]
3. Chadha J, "Insights into the monkeypox virus: Making of another pandemic within the pandemic?", Environ. Microbiol, 24, pp.4547~4560 (2022)
4. "Mpox (Monkeypox): Causes, Symptoms, Treatment & Prevention" (2023)[URL]
5. "Investigation into monkeypox outbreak in England: technical briefing 1" (2022)[URL]
6. Ahmed SF, "Vaccinia-virus-based vaccines are expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus", Viruses, 14, pp.1960~ (2022)
7. Louten J, "Essential human virology", pp.273~290 (2016), Academic Press is an imprint of Elsevier
8. Shi D, "Kinetic and structural aspects of glycosaminoglycan - Monkeypox virus protein A29 interactions using surface plasmon resonance", Molecules, 27, pp.5898~ (2022)
9. Moss B, "Membrane fusion during poxvirus entry", Semin. Cell. Dev. Biol, 60, pp.89~96 (2016)
10. Roberts KL, "Acidic residues in the membrane-proximal stalk region of vaccinia virus protein B5 are required for glycosaminoglycan-mediated disruption of the extracellular enveloped virus outer membrane", J. Gen. Virol, 90, pp.1582~1591 (2009)
11. Gray RDM, "Nanoscale polarization of the entry fusion complex of vaccinia virus drives efficient fusion", Nat. Microbiol, 4, pp.1636~1644 (2019)
12. Moss B, "Poxvirus DNA replication", Cold Spring Harb. Perspect. Biol, 5, pp.a010199~ (2013)
13. Katsafanas GC, "Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions", Cell Host Microbe, 2, pp.221~228 (2007)
14. Li H, "The land-scape of immune response to monkeypox virus", EBioMedicine, 87, pp.104424~ (2023)
15. Liang C, "Biological characteristics, biosafety prevention and control strategies for the 2022 multi-country outbreak of monkeypox", Biosaf. Health, 04, pp.376~385 (2022)
16. Reynolds MG, "Outbreaks of human monkeypox after cessation of smallpox vaccination", Trends Microbiol, 20, pp.80~87 (2012)
17. Isidro J, "Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus", Nat. Med, 28, pp.1569~1572 (2022)
18. Alcami A, "Pathogenesis of the circulating mpox virus and its adaptation to humans", Proc. Natl. Acad. Sci. USA, 120, pp.e2301662120~ (2023)
19. "Laboratory testing for the monkeypox virus: Interim guidance" (2022)[URL]
20. Luciani L, "A novel and sensitive real-time PCR system for universal detection of poxviruses", Sci. Rep, 11, pp.1798~ (2021)
21. Orba Y, "Orthopoxvirus infection among wildlife in Zambia", J. Gen. Virol, 96, pp.390~394 (2015)
22. Li Y, "Detection of monkeypox virus with real-time PCR assays", J. Clin. Virol, 36, pp.194~203 (2006)
23. Shchelkunov SN, "Species-specific identification of variola, monkeypox, cowpox, and vaccinia viruses by multiplex real-time PCR assay", J. Virol. Methods, 175, pp.163~169 (2011)
24. Kulesh DA, "Monkeypox virus detection in rodents using real-time 3'-minor groove binder TaqMan assays on the Roche LightCycler", Lab. Invest, 84, pp.1200~1208 (2004)
25. "Mpox Generic PCR Protocol" (2023)[URL]
26. Li Y, "Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA", J. Virol. Methods, 169, pp.223~227 (2010)
27. "Surveillance, case investigation and contact tracing for mpox (monkeypox): interim guidance" (2022)[URL]
28. Karem KL, "characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak", Clin. Diagn. Lab. Immunol, 12, pp.867~872 (2005)
29. Karem KL, "Characterization of acute-phase humoral immunity to Monkeypox: Use of immunoglobulin M enzyme-linked immunosorbent assay for detection of Monkeypox infection during the 2003 North American outbreak", Clin. Diagn. Lab. Immunol, 12, pp.867~872 (2005)
30. Alakunle E, "Monkeypox virus in Nigeria: Infection biology, epidemiology, and evolution", Viruses, 12, pp.1257~ (2020)
31. "Treatment Information for Healthcare Professionals" (2023)[URL]
32. "Smallpox Preparedness and Response Updates from FDA" (2023)[URL]
33. Hostetler KY, "Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity:current state of the art", Antiviral Res, 82, pp.A84~A98 (2009)
34. Kern ER, "Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir", Antimicrob. Agents Chemother, 46, pp.991~995 (2002)
35. Beadle JR, "Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro", Antimicrob. Agents Chemother, 46, pp.2381~2386 (2002)
36. Hartline CB, "Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro", J. Infect. Dis, 191, pp.396~399 (2005)
37. Siegrist EA, "Antivirals with activity against Mpox: A clinically oriented review", Clin. Infect. Dis, 76, pp.155~164 (2023)
38. Yang G, "An orally bioavailable antipoxvirus compound (ST-246)inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge", J. Virol, 79, pp.13139~13149 (2005)
39. Grosenbach DW, "Development of the small-molecule antiviral ST-246 as a smallpox therapeutic", Future Virol, 6, pp.653~671 (2011)
40. Bell E, "Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin", Virology, 325, pp.425~431 (2004)
41. Thet AK, "The use of vaccinia immune globulin in the treatment of severe Mpox. virus infection in human immunodeficiency virus", AIDS, 2023, pp.76, 1671~1673
42. Kane EM, "Adenosine N1-oxide inhibits vaccinia virus replication by blocking translation of viral early mRNAs", J. Virol, 69, pp.6352~6358 (1995)
43. Myskiw C, "Nigericin is a potent inhibitor of the early stage of vaccinia virus replication", Antiviral Res, 88, pp.304~310 (2010)
44. Myskiw C, "Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors", J. Virol, 81, pp.3027~3032 (2007)
45. Rizk JG, "Prevention and treatment of Monkeypox", Drugs, 82, pp.957~963 (2022)
46. Prichard MN, "Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections", Antimicrob. Agents Chemother, 50, pp.1336~1341 (2006)
47. Pedrali-Noy G, "Mechanism of inhibition of herpes simplex virus and vaccinia virus DNA polymerases by aphidicolin, a highly specific inhibitor of DNA replication in eucaryotes", J. Virol, 36, pp.457~464 (1980)
48. Taddie JA, "Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3'-5'exonuclease domain", J. Virol, 67, pp.4323~4336 (1993)
49. Kern ER, "Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections", Antimicrob. Agents Chemother, 53, pp.572~579 (2009)
50. Smee DF, "Antiviral activities and phosphorylation of 5-halo-2'-deoxyuridines and Nmethanocarbathymidine in cells infected with vaccinia virus", Antivir. Chem. Chemother, 19, pp.15~24 (2008)
51. Saccucci L, "Inhibition of vaccinia virus replication by peptide aptamers", Antiviral Res, 82, pp.134~140 (2009)
52. Flusin O, "A small molecule screen in yeast identifies inhibitors targeting protein-protein interactions within the vaccinia virus replication complex", Antiviral Res, 96, pp.187~195 (2012)
53. Slabaugh MB, "Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase", J. Virol, 60, pp.506~514 (1986)
54. Condit RC, "A vaccinia virus isatin-beta-thiosemicarbazone resistance mutation maps in the viral gene encoding the 132-kDa subunit of RNA polymerase", Virology, 185, pp.857~861 (1991)
55. Meis RJ, "Genetic and molecular biological characterization of a vaccinia virus gene which renders the virus dependent on isatin-beta-thiosemicarbazone (IBT)", Virology, 182, pp.442~454 (1991)
56. Prins C, "An isatin-beta-thiosemicarbazone-resistant vaccinia virus containing a mutation in the second largest subunit of the viral RNA polymerase is defective in transcription elongation", J. Biol. Chem, 279, pp.44858~44871 (2004)
57. Weiss MM, "Rethinking smallpox", Clin. Infect. Dis, 39, pp.1668~1673 (2004)
58. Spisakova M, "Ethacrynic and alpha-lipoic acids inhibit vaccinia virus late gene expression", Antiviral Res, 81, pp.156~165 (2009)
59. Charity JC, "Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin", Virology, 359, pp.227~232 (2007)
60. Baldick CJ, Jr., "Resistance of vaccinia virus to rifampicin conferred by a single nucleotide substitution near the predicted NH2 terminus of a gene encoding an Mr 62,000 polypeptide", Virology, 156, pp.138~145 (1987)
61. Deng L, "Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly", J. Virol, 81, pp.13392~13402 (2007)
62. Altmann SE, "Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone", Antiviral Res, 93, pp.305~308 (2012)
63. Ikeda S, "Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative", Antiviral Res, 8, pp.103~113 (1987)
64. Sekiguchi J, "Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin", J. Biol. Chem, 271, pp.2313~2322 (1996)
65. Sekiguchi J, "Novobiocin inhibits vaccinia virus replication by blocking virus assembly", Virology, 235, pp.129~137 (1997)
66. Byrd CM, "New class of orthopoxvirus antiviral drugs that block viral maturation", J. Virol, 78, pp.12147~12156 (2004)
67. Dubey A, "Exploration of microbially derived natural compounds against Monkeypox virus as viral core cysteine proteinase inhibitors", Viruses, 15, pp.251~ (2023)
68. Prichard MN, "Orthopoxvirus targets for the development of new antiviral agents", Antiviral Res, 94, pp.111~125 (2012)
69. Frenois-Veyrat G, "Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations", Nat. Microbiol, 7, pp.1951~1955 (2022)
70. Payne LG, "Mechanism of vaccinia virus release and its specific inhibition by N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine", J. Virol, 32, pp.614~622 (1979)
71. Schmutz C, "A mutation in the gene encoding the vaccinia virus 37,000-M(r) protein confers resistance to an inhibitor of virus envelopment and release", J. Virol, 65, pp.3435~3442 (1991)
72. Reeves PM, "Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases", J. Virol, 85, pp.21~31 (2011)
73. Newsome TP, "Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus", Cell. Microbiol, 8, pp.233~241 (2006)
74. Reeves PM, "Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases", Nat. Med, 11, pp.731~739 (2005)
75. Pollara JJ, "Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid", Antiviral Res, 88, pp.287~295 (2010)
76. Bojkova D, "Repurposing of the antibiotic nitroxoline for the treatment of mpox", J. Med. Virol, 95, pp.e28652~ (2023)
77. Kindrachuk J, "Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus", Mol. Cell. Proteomics, 11, pp.M111.015701~ (2012)
78. Beerli C, "Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility", Nat. Microbiol, 4, pp.216~225 (2019)
79. Hammarlund E, "Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox", Nat. Med, 11, pp.1005~1011 (2005)
80. Kemper AR, "Expected adverse events in a mass smallpox vaccination campaign", Eff. Clin. Pract, 5, pp.84~90 (2002)
81. Edghill-Smith Y, "Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus", Nat. Med, 11, pp.740~747 (2005)
82. Edghill-Smith Y, "Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge", J. Infect. Dis, 191, pp.372~381 (2005)
83. Kenner J, "LC16m8: an attenuated smallpox vaccine", Vaccine, 24, pp.7009~7022 (2006)
84. Maksyutov RA, "Genome stability of the vaccine strain VACDelta6", Vavilovskii Zhurnal Genet Selektsii, 26, pp.394~401 (2022)
85. "Mpox Vaccine Tracker: List of vaccine candidates in research & development" (2023)[URL]
86. Lum FM, "Monkeypox: disease epidemiology, host immunity and clinical interventions", Nat. Rev. Immunol, 22, pp.597~613 (2022)
87. Petersen BW, "Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses - Recommendations of the advisory committee on immunization practices (ACIP), 2015", MMWR Morb. Mortal. Wkly. Rep, 65, pp.257~262 (2016)
88. Pittman PR, "Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox", N. Engl. J. Med, 381, pp.1897~1908 (2019)
89. Thornhill JP, "Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022", N. Engl. J. Med, 387, pp.679~691 (2022)
90. Rao AK, "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses:Recommendations of the Advisory Committee on Immunization Practices - United States, 2022", MMWR Morb. Mortal. Wkly. Rep, 71, pp.734~742 (2022)
91. Sang Y, "Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus", Signal. Transduct. Target. Ther, 8, pp.172~ (2023)
92. Hooper JW, "DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge", Virology, 266, pp.329~339 (2000)
93. Fang Z, "Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens", Cell. Res, 33, pp.407~410 (2023)
94. Zeng J, "Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge", Emerg. Microbes. Infect, 12, pp.2204151~ (2023)
95. Freyn AW, "A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge", bioRxiv. 2022.2012.2017.520886, ~ (2022)
96. Hou F, "Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge", bioRxiv. 2022.2011.2019.517190, ~ (2022)
97. Hooper JW, "Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox", J. Virol, 78, pp.4433~4443 (2004)
98. Hooper JW, "Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates", Virology, 306, pp.181~195 (2003)
99. Mucker EM, "A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge", J. Virol, 96, pp.e0150421~ (2022)
100. Heraud JM, "Subunit recombinant vaccine protects against monkeypox", J. Immunol, 177, pp.2552~2564 (2006)
101. Hirao LA, "Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge", J. Infect. Dis, 203, pp.95~102 (2011)
102. Franceschi V, "BoHV-4-Based vector single heterologous antigen delivery protects STAT1(-", -) Mice from Monkeypoxvirus lethal challenge, 2015, pp.9, e0003850~
103. Hernaez B, "New insights into the immunomodulatory properties of poxvirus cytokine decoy receptors at the cell surface", F1000Res, 7 (2018)
104. Buchman GW, "A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge", Vaccine, 28, pp.6627~6636 (2010)
105. Xiao Y, "Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus", Vaccine, 38, pp.6007~6018 (2020)
106. Patarroyo ME, "A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria", Nature, 332, pp.158~161 (1988)
107. Lozano JM, "The search of a Malaria vaccine: The time for modified immuno-potentiating probes", Vaccines (Basel), 9, pp.115~ (2021)
108. Lozano JM, "Monkeypox: potential vaccine development strategies", Trends Pharmacol. Sci, 44, pp.15~19 (2023)
109. Bonam SR, "An overview of novel adjuvants designed for improving vaccine efficacy", Trends Pharmacol. Sci, 38, pp.771~793 (2017)
110. Blasco R, "Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein", J. Virol, 65, pp.5910~5920 (1991)
111. Fogg C, "Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions", J. Virol, 78, pp.10230~10237 (2004)
112. Ando J, "Identification of protective T-cell antigens for smallpox vaccines", Cytotherapy, 22, pp.642~652 (2020)

관련 논문AI추천